Cargando…

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis

Icotinib is a novel and the third listed epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs has been shown to be associated with the EGFR mutation status, especially exon 19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Jian, Wang, Ya-Nan, Xu, Ping, Xiang, Da-Xiong, Yang, Rui, Wei, Wei, Qu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464926/ https://www.ncbi.nlm.nih.gov/pubmed/28430623 http://dx.doi.org/10.18632/oncotarget.15475

Ejemplares similares

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Combination of icotinib, surgery, and internal-radiotherapy of a patient with lung cancer severely metastasized to the vertebrae bones with EGFR mutation: a case report
por: Qu, Li-Li, et al.
Publicado: (2015)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
por: Feng, Siyang, et al.
Publicado: (2015)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
por: Zhang, Yun, et al.
Publicado: (2021)

Ubiquitin Ligase Cbl-b Is Involved in Icotinib (BPI-2009H)-Induced Apoptosis and G1 Phase Arrest of EGFR Mutation-Positive Non-Small-Cell Lung Cancer
por: Mu, Xiaodong, et al.
Publicado: (2013)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Efficacy of icotinib in advanced lung squamous cell carcinoma
por: Liang, Shuai, et al.
Publicado: (2018)

Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2016)

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2019)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
por: Zeng, Ziqing, et al.
Publicado: (2020)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
por: Ye, Chenyang, et al.
Publicado: (2016)

Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report
por: Wu, Ka, et al.
Publicado: (2019)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
por: Chen, Jianxin, et al.
Publicado: (2022)

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
por: Xu, Jian‐ping, et al.
Publicado: (2016)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
por: Xu, Jianping, et al.
Publicado: (2016)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
por: Wang, Long, et al.
Publicado: (2021)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
por: Liu, Yu-Tao, et al.
Publicado: (2020)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma [Corrigendum]
Publicado: (2017)

Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
por: Tan, Xueyun, et al.
Publicado: (2023)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report
por: Zhang, Ping, et al.
Publicado: (2018)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
por: Wang, Junhui, et al.
Publicado: (2019)

Durable response to pulsatile icotinib for central nervous system metastases from EGFR-mutated non-small cell lung cancer: A case report
por: Li, Hui-Ying, et al.
Publicado: (2020)

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
por: Zhou, Bin, et al.
Publicado: (2022)

Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases
por: Fan, Yun, et al.
Publicado: (2017)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
por: Shen, Yan-Wei, et al.
Publicado: (2016)

Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report
por: Chen, Yu-Qing, et al.
Publicado: (2021)

Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment: A case report
por: Dai, Limeng, et al.
Publicado: (2018)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
por: Xu, Jianping, et al.
Publicado: (2017)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
por: Zhang, Ying, et al.
Publicado: (2015)

A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer
por: Zhang, Bo
Publicado: (2023)

The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis
por: Wang, Lulu, et al.
Publicado: (2018)

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
por: Jiang, Zhansheng, et al.
Publicado: (2021)

Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone
por: Xu, Yunhua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_18nosm4r2ifrrg6rk1sa07qr0j